GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Shiller PE Ratio

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Shiller PE Ratio : 99.94 (As of May. 15, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Shiller PE Ratio?

As of today (2024-05-15), Catalyst Pharmaceuticals's current share price is $16.99. Catalyst Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $0.17. Catalyst Pharmaceuticals's Shiller PE Ratio for today is 99.94.

The historical rank and industry rank for Catalyst Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

CPRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 86.59   Med: 142.65   Max: 950.5
Current: 99.94

During the past years, Catalyst Pharmaceuticals's highest Shiller PE Ratio was 950.50. The lowest was 86.59. And the median was 142.65.

CPRX's Shiller PE Ratio is ranked worse than
84.77% of 151 companies
in the Biotechnology industry
Industry Median: 35.74 vs CPRX: 99.94

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.190. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.17 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalyst Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Catalyst Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Shiller PE Ratio Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 482.32 122.70

Catalyst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 235.49 117.26 112.71 122.70 96.56

Competitive Comparison of Catalyst Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Shiller PE Ratio falls into.



Catalyst Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Catalyst Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=16.99/0.17
=99.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.19/129.4194*129.4194
=0.190

Current CPI (Mar. 2024) = 129.4194.

Catalyst Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.050 100.560 -0.064
201409 -0.070 100.428 -0.090
201412 -0.050 99.070 -0.065
201503 -0.070 99.621 -0.091
201506 -0.060 100.684 -0.077
201509 -0.050 100.392 -0.064
201512 -0.070 99.792 -0.091
201603 -0.070 100.470 -0.090
201606 -0.060 101.688 -0.076
201609 -0.050 101.861 -0.064
201612 -0.050 101.863 -0.064
201703 -0.060 102.862 -0.075
201706 -0.050 103.349 -0.063
201709 -0.050 104.136 -0.062
201712 -0.060 104.011 -0.075
201803 -0.060 105.290 -0.074
201806 -0.060 106.317 -0.073
201809 -0.080 106.507 -0.097
201812 -0.140 105.998 -0.171
201903 -0.010 107.251 -0.012
201906 0.100 108.070 0.120
201909 0.130 108.329 0.155
201912 0.070 108.420 0.084
202003 0.100 108.902 0.119
202006 0.090 108.767 0.107
202009 0.410 109.815 0.483
202012 0.110 109.897 0.130
202103 0.070 111.754 0.081
202106 0.110 114.631 0.124
202109 0.100 115.734 0.112
202112 0.090 117.630 0.099
202203 0.120 121.301 0.128
202206 0.200 125.017 0.207
202209 0.200 125.227 0.207
202212 0.220 125.222 0.227
202303 0.260 127.348 0.264
202306 0.330 128.729 0.332
202309 -0.290 129.860 -0.289
202312 0.310 129.419 0.310
202403 0.190 129.419 0.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalyst Pharmaceuticals  (NAS:CPRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Catalyst Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Executives
Molly Harper director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande officer: Chief Accounting Officer 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito officer: Chief Medical Officer 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller officer: VP Development & Management 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany director, 10 percent owner, officer: President and Chief Executive C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del officer: Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd officer: Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe director 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram officer: Chief Product Devel. Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan officer: Chief Commercial Officer C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship officer: V.P. of Regulatory Operations 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Headlines

From GuruFocus

JW Asset Management, LLC Buys 3, Sells 2 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-13-2023